Spots Global Cancer Trial Database for Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo)

Official Title: Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)

Study ID: NCT01291082

Conditions

Breast Cancer

Interventions

Study Description

Brief Summary: Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.

Detailed Description: About 50 patients with a proven breast cancer and bone metastases will be included. First step : staging * nuclear bone scan * Positron Emission Tomography (PET/CT) * MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and Diffusion weighted imaging (DWI),no contrast administration Aim : * Validation of whole body diffusion weighted imaging in detection of bone metastases and visceral metastases, comparing to Bone scan en PET/CT results. * To calculate cut-off values for DWI for bone and visceral metastases. Second step : therapy follow-up/therapy assessment. * Two groups of patients (oncologist takes the decision about therapy) 1. Patients treated by chemotherapy 2. Patients treated by hormonal therapy * on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR (same protocol, no contrast) will be performed. End-point: Whole body MR with DWI is useful and reliable to assess the treatment response.